[go: up one dir, main page]

PE20050247A1 - Saquinavir mesilato, forma de dosificacion oral - Google Patents

Saquinavir mesilato, forma de dosificacion oral

Info

Publication number
PE20050247A1
PE20050247A1 PE2004000651A PE2004000651A PE20050247A1 PE 20050247 A1 PE20050247 A1 PE 20050247A1 PE 2004000651 A PE2004000651 A PE 2004000651A PE 2004000651 A PE2004000651 A PE 2004000651A PE 20050247 A1 PE20050247 A1 PE 20050247A1
Authority
PE
Peru
Prior art keywords
oral dosage
dosage form
saquinavir mesilate
mesilate
saquinavir
Prior art date
Application number
PE2004000651A
Other languages
English (en)
Inventor
Antonio A Albano
Martin Howard Infeld
Wantanee Phuapradit
Lin Zhang
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34068244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050247(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20050247A1 publication Critical patent/PE20050247A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA AUNA FORMA DE DOSIFICACION ORAL UNITARIA QUE CONTIENE 60 A 80% DE FORMA CRISTALINA DE MESILATO DE SAQUINAVIR MICRONIZADO CON UN PESO DE 250-700 mg COMO BASE LIBRE, 4 A 8% DE UN AGLUTINANTE SOLUBLE EN AGUA COMO POLIVINILPIRROLIDONA, UN EXCIPIENTE FARMACEUTICO COMO LACTOSA MONOHIDRATADA CON PARTICULAS DE 100-150 MICRAS, UN DESINTREGANTE COMO CROSCARAMELOSA SODICA O CROSPOVIDONA, UN LUBRICANTE COMO ESTEARATO DE MAGNESIO, ADEMAS DE CONTENER CELULOSA MICROCRISTALINA. DICHA FORMA SE HALLA COMO TABLETA, CAPSULA O CAPUCHON; Y PUEDE EMPLEARSE EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL VIH
PE2004000651A 2003-07-11 2004-07-07 Saquinavir mesilato, forma de dosificacion oral PE20050247A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48660003P 2003-07-11 2003-07-11
US56820404P 2004-05-05 2004-05-05

Publications (1)

Publication Number Publication Date
PE20050247A1 true PE20050247A1 (es) 2005-04-13

Family

ID=34068244

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000651A PE20050247A1 (es) 2003-07-11 2004-07-07 Saquinavir mesilato, forma de dosificacion oral

Country Status (24)

Country Link
US (2) US20050009811A1 (es)
EP (1) EP1646369B1 (es)
JP (2) JP4608488B2 (es)
KR (2) KR20070087194A (es)
AU (1) AU2004255436B2 (es)
BR (1) BRPI0412523A (es)
CA (1) CA2531486C (es)
CO (1) CO5640069A2 (es)
CR (1) CR8172A (es)
EA (1) EA015349B1 (es)
EC (1) ECSP066274A (es)
HK (1) HK1089959A1 (es)
IL (1) IL172890A (es)
MA (1) MA27904A1 (es)
MX (1) MXPA06000363A (es)
MY (1) MY140413A (es)
NO (1) NO20060313L (es)
NZ (1) NZ544585A (es)
PA (1) PA8606001A1 (es)
PE (1) PE20050247A1 (es)
RS (1) RS20060009A (es)
TN (1) TNSN06003A1 (es)
TW (1) TWI356711B (es)
WO (1) WO2005004836A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
AU2004255436B2 (en) * 2003-07-11 2006-11-30 F. Hoffmann-La Roche Ag Saquinavir mesylate oral dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
US10952968B2 (en) 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
US20210379089A1 (en) * 2018-10-23 2021-12-09 Eastern Virginia Medical School Pharmaceutical compositions and methods of making on demand solid dosage formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
DE69322764T2 (de) * 1992-10-09 1999-05-06 Kanegafuchi Kagaku Kogyo K.K., Osaka Herstellungsmethode für feines granulat
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
KR20010042566A (ko) * 1998-04-09 2001-05-25 프리돌린 클라우스너, 롤란드 비. 보레르 압축된 기체 및 계면활성제중에 용해시킴으로써, 크기가마이크론 이하인 입자를 제조하는 방법
CA2354472C (en) * 1998-12-17 2009-02-24 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EP1247456A3 (en) * 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
AU2004255436B2 (en) * 2003-07-11 2006-11-30 F. Hoffmann-La Roche Ag Saquinavir mesylate oral dosage form

Also Published As

Publication number Publication date
RS20060009A (en) 2008-06-05
MA27904A1 (fr) 2006-05-02
EP1646369A2 (en) 2006-04-19
HK1089959A1 (en) 2006-12-15
KR20070087194A (ko) 2007-08-27
JP2009501694A (ja) 2009-01-22
IL172890A (en) 2013-11-28
CA2531486C (en) 2012-10-02
BRPI0412523A (pt) 2006-09-19
JP2010280707A (ja) 2010-12-16
PA8606001A1 (es) 2005-03-03
MXPA06000363A (es) 2006-03-28
NO20060313L (no) 2006-02-09
CR8172A (es) 2006-10-04
MY140413A (en) 2009-12-31
NZ544585A (en) 2008-04-30
KR100767271B1 (ko) 2007-10-17
TNSN06003A1 (en) 2007-10-03
KR20060056320A (ko) 2006-05-24
EA015349B1 (ru) 2011-06-30
TWI356711B (en) 2012-01-21
EP1646369B1 (en) 2019-04-10
IL172890A0 (en) 2006-06-11
WO2005004836A3 (en) 2005-05-12
WO2005004836A2 (en) 2005-01-20
AU2004255436A1 (en) 2005-01-20
TW200505504A (en) 2005-02-16
US20090054481A1 (en) 2009-02-26
AU2004255436B2 (en) 2006-11-30
CA2531486A1 (en) 2005-01-20
ECSP066274A (es) 2006-10-25
CO5640069A2 (es) 2006-05-31
EA200600156A1 (ru) 2006-08-25
US20050009811A1 (en) 2005-01-13
JP4608488B2 (ja) 2011-01-12

Similar Documents

Publication Publication Date Title
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
MY146988A (en) Fexofenadine suspension formulation
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
NO20006027L (no) Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser
AR027528A1 (es) Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos
TW200505506A (en) Pharmaceutical safety dosage forms
NO20055393L (no) Oralt desintegrerende tabletter
CO5070571A1 (es) Preparado farmaceutico de moxifloxacina
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
PE20050247A1 (es) Saquinavir mesilato, forma de dosificacion oral
AR074739A1 (es) Comprimidos de capecitabina de disgregacion rapida
BR112012009857A2 (pt) composições farmacêuticas sólidas contendo um inibidor de integrase
CO6150122A2 (es) Comprimidos pediatricos de capecitabina
JP2007515426A5 (es)
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
HUP0400127A2 (hu) Paracetamolt tartalmazó lenyelhető tabletta
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
AR038494A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr
MX2023007601A (es) Preparacion solida oral.
BR112023003572A2 (pt) Formulação oral sólida de utidelona
MX2023001014A (es) Composiciones farmaceuticas que comprenden venglustat.
WO2008060890A3 (en) Darusentan oral dosage form

Legal Events

Date Code Title Description
FC Refusal